Darrell E. White, MD

Man, if I had a nickel for every time I have heard the phrase “the customer is always right.” I mean, am I right or am I right?

  The FDA issued a complete response letter for the resubmission of the reproxalap new drug application for the treatment of signs and symptoms of dry eye disease, according to a press release from Aldeyra Therapeutics.

It’s a mad, mad, mad world out there, folks.

Last month, I outlined my philosophy for treating not just dry eye disease, or DED, but pretty much everything there is to be treated in eye care.

We’re still in the first quarter of the insurance plan year.

OK, I know what you are thinking. Am I not the same guy who has been spouting off about our new dry eye world of “and,” not “either/or?” It is only a little more than a year in this new treatment paradigm, and I am already changing my tune?

Happy New Year! How was your holiday season?

Man, did that year go fast!

’Twas a time, not so very long ago, when eye doctors treating dry eye disease had heart-to-hearts about how we should discuss the latency between onset of treatment and when patients would finally begin to feel some relief.

It seems as if eye doctors who treat the ocular surface and eyelids have been looking for a safe and effective treatment for the signs and symptoms of meibomian gland disease forever.